First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway

Clinical Cancer Research

Volumn 18, Issue 8, 2012, Pages 2220-2229

  Manu, Kanjoormana A ^a   Shanmugam, Muthu K ^a   Ramachandran, Lalitha ^a   Li, Feng ^a   Fong, Chee Wai ^c   Kumar, Alan Prem ^a,b,f   Tan, Patrick ^b,d,e   Sethi, Gautam ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DAVOS LIFE SCIENCE PTE LTD   (Singapore)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CD31 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLIN D1; CYCLOOXYGENASE 2; GAMMA TOCOTRIENOL; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; TUMOR MARKER; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENE PRODUCT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; CYCLIN D1; CYCLOOXYGENASE 2; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MITOCHONDRIA; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CXCR4; REPRESSOR PROTEINS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN E; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859834841     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2470     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24: 2903-9. (Pubitemid 46630593)
4. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One 2011;6:e16694.
5. Nam SY, Ko YS, Jung J, Yoon J, Kim YH, Choi YJ, et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor- kappaB promotes gastric tumour growth and angiogenesis. Br J Cancer 2011;104:166-74.
6. Chao X, Zao J, Xiao-Yi G, Li-Jun M, Tao S. Blocking of PI3K/AKT induces apoptosis by its effect on NF-kappaB activity in gastric carcinoma cell line SGC7901. Biomed Pharmacother 2010;64:600-4.
7. Shuai XM, Han GX, Wang GB, Chen JH. Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells. World J Gastroenterol 2006;12:1766-9.
8. Schimanski CC, Galle PR, Moehler M. Chemokine receptor CXCR4- prognostic factor for gastrointestinal tumors. World J Gastroenterol 2008;14:4721-4.
9. Park ES, Do IG, Park CK, Kang WK, Noh JH, Sohn TS, et al. Cyclooxygenase- 2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res 2009;15:291-8.
10. Maeda S, Yoshida H, Ogura K, Mitsuno Y, Hirata Y, Yamaji Y, et al. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 2000;119:97-108.
11. Hatz RA, Rieder G, Stolte M, Bayerdorffer E, Meimarakis G, Schildberg FW, et al. Pattern of adhesion molecule expression on vascular endothelium in Helicobacter pylori-associated antral gastritis. Gastroenterology 1997;112:1908-19. (Pubitemid 27240777)
12. Wada S. Cancer preventive effects of vitamin E. Curr Pharm Biotechnol 2011;13:156-64.
13. Ahn KS, Sethi G, Krishnan K, Aggarwal BB. Gamma-to-cotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J Biol Chem 2007;282:809-20. (Pubitemid 47076658)
14. Aggarwal BB, Sundaram C, Prasad S, Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol 2010;80:1613-31.
15. Wada S. Chemoprevention of tocotrienols: the mechanism of antiproliferative effects. Forum Nutr 2009;61:204-16.
16. Sun W, Xu W, Liu H, Liu J, Wang Q, Zhou J, et al. gamma-Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells. J Nutr Biochem 2009;20:276-84.
17. Sun W, Wang Q, Chen B, Liu J, Liu H, Xu W. Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. Br J Nutr 2008;99:1247-54.
18. Liu HK, Wang Q, Li Y, Sun WG, Liu JR, Yang YM, et al. Inhibitory effects of gamma-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells. J Nutr Biochem 2010;21: 206-13.
19. Bi S, Liu JR, Li Y, Wang Q, Liu HK, Yan YG, et al. gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line. Toxicology 2010;274:27-33.
20. Rajendran P, Li F, Manu KA, Shanmugam MK, Loo SY, Kumar AP, et al. gamma-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol 2011;163:283-98.
21. Chang PN, Yap WN, Lee DT, Ling MT, Wong YC, Yap YL. Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutr Cancer 2009;61:357-66.
22. Samant GV, Wali VB, Sylvester PW. Anti-proliferative effects of gamma- tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif 2010;43:77-83.
23. Xu W, Du M, Zhao Y, Wang Q, Sun W, Chen B. γ-Tocotrienol inhibits cell viability through suppression of beta-catenin/Tcf signaling in human colon carcinoma HT-29 cells. J Nutr Biochem. 2011 Aug 16. [Epub ahead of print].
24. Yap WN, Chang PN, Han HY, Lee DT, Ling MT, Wong YC, et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br J Cancer 2008;99: 1832-41.
25. Gould MN, Haag JD, Kennan WS, Tanner MA, Elson CE. A comparison of tocopherol and tocotrienol for the chemoprevention of chemically induced rat mammary tumors. Am J Clin Nutr 1991;53:1068S-70S. (Pubitemid 21898877)
26. Yap WN, Zaiden N, Luk SY, Lee DT, Ling MT, Wong YC, et al. In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology 2010;85: 248-58.
27. McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp Biol Med (Maywood) 2007;232:523-31. (Pubitemid 46524474)
28. Hiura Y, Tachibana H, Arakawa R, Aoyama N, Okabe M, Sakai M, et al. Specific accumulation of gamma- and delta-tocotrienols in tumor and their antitumor effect in vivo. J Nutr Biochem 2009;20:607-13.
29. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, et al. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res 2010;70:8695-705.
30. Samant GV, Sylvester PW. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif 2006;39:563-74. (Pubitemid 44760206)
31. Eitsuka T, Nakagawa K, Miyazawa T. Down-regulation of telomerase activity in DLD-1 human colorectal adenocarcinoma cells by tocotrienol. Biochem Biophys Res Commun 2006;348:170-5. (Pubitemid 44163497)
32. Li F, Tan W, Kang Z, Wong CW. Tocotrienol enriched palm oil prevents atherosclerosis through modulating the activities of peroxisome proliferators-activated receptors. Atherosclerosis 2010; 211:278-82.
33. Shibata A, Nakagawa K, Sookwong P, Tsuduki T, Tomita S, Shirakawa H, et al. Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxiainducible factor-1alpha. J Nutr 2008;138:2136-42.
34. Yap WN, Zaiden N, Tan YL, Ngoh CP, Zhang XW, Wong YC, et al. Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells. Cancer Lett 2010;291:187-99.
35. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, et al. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 2011;17:1425-39.
36. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, et al. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004;199: 249-58. (Pubitemid 38962737)
37. Yu LL, Dai N, Yu HG, Sun LM, Si JM. Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells. Oncol Rep 2010;24:113-9.
38. Sethi G, Tergaonkar V. Potential pharmacological control of the NF-κB pathway. Trends Pharmacol Sci 2009;30:313-21.
39. Yu LL, Wu JG, Dai N, Yu HG, Si JI. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-kappaB transcription factor. Oncol Rep 2011;26:1197-203.
40. Yang MD, Lai KC, Lai TY, Hsu SC, Kuo CL, Yu CS, et al. Phenethyl isothiocyanate inhibits migration and invasion of human gastric cancer AGS cells through suppressing MAPK and NF-kappaB signal pathways. Anticancer Res 2010;30:2135-43.
41. Li Y, Sun WG, Liu HK, Qi GY, Wang Q, Sun XR, et al. γ-Tocotrienol inhibits angiogenesis of human umbilical vein endothelia cell induced by cancer cell. J Nutr Biochem 2011;22:1127-36.
42. Wali VB, Bachawal SV, Sylvester PW. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood) 2009;234:639-50.
43. Yang Z, Xiao H, Jin H, Koo PT, Tsang DJ, Yang CS. Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int J Cancer 2010;126:852-63.
44. Shirode AB, Sylvester PW. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother 2010;64:327-32.
45. Bachawal SV, Wali VB, Sylvester PW. Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res 2010;30: 429-37.
46. Bachawal SV, Wali VB, Sylvester PW. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 2010;10:84.